A Randomized-Controlled Trial Targeting Cognition in Early Alzheimer's Disease by Improving Sleep with Trazodone (REST).
Estelle Eyob, Jacob S Shaw, Arnold Bakker...
https://pubmed.ncbi.nlm.nih.gov/39422935/Actively Recruiting
Led by Johns Hopkins University · Updated on 2026-06-17
100
Participants Needed
1
Research Sites
48 weeks
Total Duration
Researchers are evaluating the effects of trazodone on sleep quality, memory related to the hippocampus, and brain activity in people with Amnestic Mild Cognitive Impairment aMCI who have sleep complaints. The study aims to see if trazodone can increase total sleep time and the time spent in deep sleep stages known as Slow Wave Sleep SWS. This is a phase 2, randomized, placebo-controlled, double-blind crossover trial involving 100 participants. Participants will receive 50 mg of trazodone at bedtime for 4 weeks, followed by a 4-week washout period, then 4 weeks of placebo, or vice versa. This crossover design allows each participant to serve as their own control. The 4-week washout period is planned to fully clear trazodone from the body before switching treatments. During the study, participants will be assessed for changes in total sleep duration, SWS duration and intensity, sleep onset latency, sleep fragmentation, and self-reported sleep quality using the Pittsburgh Sleep Quality Index and Epworth Sleepiness Score. Memory performance and hippocampal brain activity during memory tasks will also be measured. These assessments take place from baseline through up to 12 weeks. Safety and ability to undergo MRI scans are monitored as well.
CONDITIONS
Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone
B
Barry Greenberg, PhD
P
Paul Rosenberg, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Johns Hopkins University
Lead Sponsor
National Institute on Aging (NIA)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Trazodone | Placebo |
|---|---|---|
| What it is | An investigational 50 mg trazodone dose taken at bedtime for 4 weeks | An identical-appearing placebo taken at bedtime for 4 weeks |
| Role in trial | Investigational treatment evaluated for effects on sleep and memory in a crossover design | Control comparator used to identify trazodone-specific effects |
| Primary use | To improve total sleep time, slow wave sleep, sleep onset, fragmentation, and self-reported sleep quality | Same outcome measurements without active drug influence |
| How it is given or performed | Given nightly at bedtime for 4 weeks, with participants crossing over after washout | Given nightly at bedtime for 4 weeks, with crossover after washout |
| Evidence status | Sleep and cognition benefits are under study; no conclusive results yet | Placebo serves as control to detect treatment effects; efficacy of placebo per se not expected |
| Important risks | Potential sedative‑related risks such as next‑day drowsiness or falls have not been established in this trial | No known physiological risks from placebo use |
| Important limitations | Effectiveness and safety in early Alzheimer’s‑related MCI remain unproven until results are available | Cannot inform on long‑term effects or generalizability beyond this crossover context |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 4 weeks
Participants take either trazodone 50 mg at bedtime or placebo for 4 weeks.
Duration - 4 weeks
Participants have a 4-week break to allow the medication to clear from their system before switching treatments.
Duration - 4 weeks
Participants take the alternate treatment (placebo or trazodone 50 mg) for 4 weeks.
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Estelle Eyob, Jacob S Shaw, Arnold Bakker...
https://pubmed.ncbi.nlm.nih.gov/39422935/Johns Hopkins University
Lead Sponsor
National Institute on Aging (NIA)
Collaborating Sponsor